Vitrisa Therapeutics is a privately held, preclinical stage, biotech company headquartered in the San Francisco Bay Area. The company is focused on a proprietary suite of technologies for the discovery & development of optimized ocular therapeutics with the potential to address the underlying mechanisms of vision loss in a wide range of ocular diseases. Our goal is to bring therapeutics that preserve or restore vision to people suffering from sight threatening ocular diseases - with an initial emphasis on orphan and rare pediatric ocular indications.